Key result
In patients with type 1 diabetes and microalbuminuria treated with ACE inhibitors, progression to proteinuria occurred at 6.3/100 person-years, predicted by poor glycemic control and high cholesterol.
Why the study?
What are the determinants of progression from microalbuminuria to proteinuria in patients with type 1 diabetes treated with ACE inhibitors?
Cohort (n=373)
What are the determinants of progression from microalbuminuria to proteinuria in patients with type 1 diabetes treated with ACE inhibitors?
Despite ACE inhibitor treatment, many patients with type 1 diabetes and microalbuminuria progress to proteinuria, driven largely by poor glycemic control and elevated cholesterol.
No takes yet. Share an insight, caveat, or question.
Progression persists despite ACE inhibitors; leaves open whether targeting glycemia and lipids alters risk in type 1 diabetes.
Ficociello et al. (2007) conducted a cohort in Type 1 diabetes and microalbuminuria (n=373). Angiotensin-converting enzyme inhibitors (ACE-I) was evaluated on Progression to proteinuria (median urinary albumin excretion >299 mug/min during a 2-yr interval). In patients with type 1 diabetes and microalbuminuria treated with ACE inhibitors, progression to proteinuria occurred at 6.3/100 person-years, predicted by poor glycemic control and high cholesterol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: